Last reviewed 2026-04-20 · How we verify

Rubraca (RUCAPARIB)

Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies.

At a glance

Mechanism of action

Rucaparib works by blocking PARP enzymes, which are crucial for repairing damaged DNA. This leads to the accumulation of DNA damage in cancer cells, triggering cell death. The effect is more pronounced in cells with defects in other DNA repair mechanisms, such as BRCA1/2 mutations.

Approved indications

• Maintenance treatment of BRCA-mutated recurrent ovarian cancer
• Treatment of BRCA-mutated mCRPC

Common side effects

• nausea
• asthenia/fatigue
• anemia/hemoglobin decreased
• AST/ALT increased
• vomiting
• diarrhea
• decreased appetite
• thrombocytopenia/platelet count decreased
• dysgeusia
• neutropenia/neutrophil count decreased
• blood creatinine increased
• dyspnea

Key clinical trials

• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (PHASE2)
• Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer (PHASE2)
• Pan Tumor Rollover Study (PHASE2)
• A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
• Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer (PHASE1, PHASE2)
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (PHASE3)
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.